Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes through a 20 years’ duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Source:2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

About the Author

Stephanie Figon, MS, RDN, LD

Founder of NutriScape.NET. As a dietitian since 1992, Steph Figon has had experiences in consulting, 15 years in clinical, and has operated a private practice nutrition counseling office for since 2011. Connect on Linkedin

Tags:

Related Posts